AM-Pharma reports excellent results from recAP Phase We trial for Acute Kidney Injury AM-Pharma B.

AM-Pharma reports excellent results from recAP Phase We trial for Acute Kidney Injury AM-Pharma B What is a Synthroid .V., a biopharmaceutical company centered on the development of recAP for inflammatory indications, announces the outcomes of its Phase I trial with both solitary and multiple ascending doses, which demonstrate that recAP can be safe and well tolerated at all dosages. In total 50 healthy feminine and man volunteers were included in the randomised, double-blind, placebo-controlled, first-in-human, one and multiple dosage escalation study, to investigate protection, tolerability, and pharmacokinetics of recAP intravenously administered.

AMPAC Fine Chemical substances receives Environmental Sustainability and Responsibility Award AMPAC Fine Chemicals LLC , a subsidiary of American Pacific Company announced today that it received environmentally friendly Responsibility and Sustainability Award at the Annual Statewide Environmental Summit, sponsored by the California Manufacturers and Technology Association , the Industrial Environmental Association and the Chemical Industry Council of California held in NORTH PARK. This is the many prestigious award available from all three companies and gains substantial recognition from the State of California Department of TOXINS Control and other state and regional regulatory firms for environmental and corporate responsibility. The award was presented for AFC’s successful efforts over the past several years to improve pollution prevention and sustainability in their manufacturing procedures.